# After the PCAC Votes: Category 1 Interim Access vs Waiting for Rulemaking
> Note: PeptIQ is not a medical provider or law firm. This article is for education only and does not give medical or legal advice. A committee recommendation is not FDA approval, and it does not by itself authorize a pharmacy to compound a drug.
The July 23 and 24, 2026 meeting of FDA's Pharmacy Compounding Advisory Committee produced a clear result. The committee recommended six nominated peptide substances for inclusion on the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. Emideltide, often called DSIP, was the only peptide considered at the meeting that did not receive a favorable recommendation.
Those votes matter. They also left the hardest practical question unanswered.
Should FDA treat the six recommended substances as Category 1 candidates and allow interim compounding under enforcement discretion, or should patients, prescribers, and pharmacies wait until notice-and-comment rulemaking is complete?
There is no clean answer. Interim access could move demand into licensed pharmacies sooner. It could also put pharmacies in a legally exposed position if FDA has not stated what conduct it will tolerate. Waiting offers a firmer rule, but a rulemaking process can take 12 to 24 months. During that gap, demand does not disappear. It often moves to sellers with less oversight.
What the committee actually decided
PCAC advises FDA on pharmacy compounding questions. Its members review the record for nominated bulk drug substances and vote on whether the substances should be placed on the list used for patient-specific compounding under section 503A of the Federal Food, Drug, and Cosmetic Act.
The July votes were recommendations to FDA. They were not:
- approvals of the peptides as drugs
- findings that the peptides are safe or effective for every promoted use
- prescriptions for any patient
- immediate additions to the final 503A Bulks List
- permission for research vendors to sell products for human use
That distinction has been mangled in social posts since the meeting. "PCAC recommended" is accurate. "FDA approved" is false.
FDA still has to decide how to act on the recommendations. A final addition to the Bulks List generally requires notice-and-comment rulemaking. FDA publishes a proposed rule, accepts public comments, reviews the record, and then may issue a final rule. Twelve to 24 months is a reasonable planning range, not a promised deadline.
Why Category 1 is part of the argument
FDA has used interim categories while it evaluates nominated substances. Category 1 has generally covered substances nominated with enough supporting information for FDA to continue evaluating them. Under an enforcement policy, FDA may state that it does not intend to take action against certain compounding while review remains open, provided other legal conditions are met.
This is where language has to stay precise. Category 1 is not the final Bulks List. Enforcement discretion is not a legal right. It is an agency statement about enforcement priorities, and FDA can define, narrow, or revise it.
Supporters of interim treatment argue that the July votes changed the record. An expert advisory committee reviewed the nominations and recommended six substances. In their view, FDA should acknowledge that result now instead of leaving the substances in the same practical position they occupied before the meeting.
The case for interim access
The strongest argument for interim access is supply quality.
Patients already seeking these peptides may turn to products labeled "research use only," overseas sellers, or clinics that cannot clearly identify the dispensing pharmacy. Moving some of that demand to state-licensed 503A pharmacies would bring patient-specific prescriptions, pharmacist controls, documented lots, and established quality procedures into the transaction.
Interim access could also give clinicians a clearer record. A named pharmacy, a known concentration, and a consistent formulation make adverse-event review and outcome tracking more useful. That does not fix a thin evidence base, but it removes some avoidable uncertainty.
Still, the case should not be oversold. A licensed compounder does not turn an investigational peptide into an approved drug. Pharmacy quality controls address identity, strength, sterility, and process. They do not prove clinical benefit.
The case for waiting
The case for waiting starts with legal clarity.
